[Skip to Content]
[Skip to Content Landing]

Effectiveness of Sequential Psychological and Medication Therapies for Insomnia DisorderA Randomized Clinical Trial

Educational Objective
To evaluate the comparative efficacy of 4 treatment sequences involving psychological and medication therapies for insomnia and examine the moderating effect of psychiatric disorders on insomnia outcomes.
1 Credit CME
Key Points

Questions  What should be first-line treatment in the management of insomnia disorder, and is there an added value to providing a second treatment for those who fail initial therapy?

Findings  In a randomized clinical trial of 211 adults with insomnia disorder, first-stage treatment involving behavior therapy or zolpidem medication produced similar response and remission rates. Adding a second-stage therapy significantly increased the percentage of responders and remitters among patients treated initially with behavior therapy but not among those treated initially with medication.

Meaning  Sequential treatments involving cognitive behavioral therapy and medication are an effective strategy for insomnia management.

Abstract

Importance  Despite evidence of efficacious psychological and pharmacologic therapies for insomnia, there is little information about what first-line treatment should be and how best to proceed when initial treatment fails.

Objective  To evaluate the comparative efficacy of 4 treatment sequences involving psychological and medication therapies for insomnia and examine the moderating effect of psychiatric disorders on insomnia outcomes.

Design, Setting, and Participants  In a sequential multiple-assignment randomized trial, patients were assigned to first-stage therapy involving either behavioral therapy (BT; n = 104) or zolpidem (zolpidem; n = 107), and patients who did not remit received a second treatment involving either medication (zolpidem or trazodone) or psychological therapy (BT or cognitive therapy [CT]). The study took place at Institut Universitaire en Santé Mentale de Québec, Université Laval, Québec City, Québec, Canada, and at National Jewish Health, Denver, Colorado, and enrollment of patients took place from August 2012 through July 2017.

Main Outcomes and Measures  The primary end points were the treatment response and remission rates, defined by the Insomnia Severity Index total score.

Results  Patients included 211 adults (132 women; mean [SD] age, 45.6 [14.9] years) with a chronic insomnia disorder, including 74 patients with a comorbid anxiety or mood disorder. First-stage therapy with BT or zolpidem produced equivalent weighted percentages of responders (BT, 45.5%; zolpidem, 49.7%; OR, 1.18; 95% CI, 0.60-2.33) and remitters (BT, 38.03%; zolpidem, 30.3%; OR, 1.41; 95% CI, 0.75-2.65). Second-stage therapy produced significant increases in responders for the 2 conditions, starting with BT (BT to zolpidem, 40.6% to 62.7%; OR, 2.46; 95% CI, 1.14-5.30; BT to CT, 50.1% to 68.2%; OR, 2.09; 95% CI, 1.01-4.35) but no significant change following zolpidem treatment. Significant increase in percentage of remitters was observed in 2 of 4 therapy sequences (BT to zolpidem, 38.1% to 55.9%; OR, 2.06; 95% CI, 1.04-4.11; zolpidem to trazodone, 31.4% to 49.4%; OR, 2.13; 95% CI, 0.91-5.00). Although response/remission rates were lower among patients with psychiatric comorbidity, treatment sequences that involved BT followed by CT or zolpidem followed by trazodone yielded better outcomes for patients with comorbid insomnia. Response and remission rates were well sustained through the 12-month follow-up.

Conclusions and Relevance  Behavioral therapy and zolpidem medication produced equivalent response and remission rates. Adding a second treatment produced an added value for those whose insomnia failed to remit with initial therapies.

Trial Registration  ClinicalTrials.gov Identifier: NCT01651442

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Corresponding Author: Charles M. Morin, PhD, École de Psychologie, Université Laval, 2325, rue des Bibliothèques, Québec, QC G1V 0A6, Canada (cmorin@psy.ulaval.ca).

Accepted for Publication: April 18, 2020.

Published Online: July 8, 2020. doi:10.1001/jamapsychiatry.2020.1767

Author Contributions: Drs Morin and Edinger had access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Morin and Edinger were principal investigators.

Concept and design: Morin, Edinger, Krystal, Belanger.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Morin, Edinger, Beaulieu-Bonneau, Simmons.

Critical revision of the manuscript for important intellectual content: Morin, Beaulieu-Bonneau, Ivers, Krystal, Guay, Belanger, Cartwright, Lamy, Busby.

Statistical analysis: Ivers.

Obtained funding: Morin, Edinger, Krystal.

Administrative, technical, or material support: Morin, Edinger, Beaulieu-Bonneau, Krystal, Simmons, Lamy.

Supervision: Morin, Edinger, Ivers, Guay, Belanger, Lamy.

Conflict of Interest Disclosures: Dr Morin has served as a consultant for Abbot, Eisai, Merck, Philips, and Weight Watchers and received research support from Idorsia and Canopy Health. Dr Edinger has received research support from Merck and Philips/Respironics. Ms Cartwright received research grant support from the National Institutes of Health, Janssen, Jazz Axsome, and Reveal Biosensors and served as a consultant to Eisai, Ferring, Galderma, Harmony Biosciences, Idorsia, Jazz, Janssen, Takeda, Merck, Neurocrine, Pernix, and Physician’s Seal. Dr Krystal reported grants from the National Institutes of Health, Patient-Centered Outcomes Research Institute, Axsome, and Reveal Biosensors; grants and personal fees from Janssen, Jazz, personal fees from Evecxia; and personal fees from Sage, Ferring, Galderma, Harmony Biosciences, Eisai, Idorsia, Neurocrine, Merck, and Takeda outside the submitted work. No other disclosures were reported.

Funding/Support: This study was funded by the National Institute of Mental Health (MH091053).

Role of the Funder/Sponsor: The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Data Sharing Statement: See Supplement 3.

Additional Information: The Data and Safety Monitoring Board (DSMB) was composed of 3 members including Daniel Almirall (Chair), Vaughn McCall, and Richard Bootzin. The DSMB committee was responsible for safeguarding the interests of study participants, assessing the safety and efficacy of study procedures, and monitoring the overall conduct of the study. The DSMB completed an annual review of the trial conduct. This committee was independent from the sponsor and declared no competing interests.

References
1.
American Psychiatric Association.  Diagnostic and Statistical Manual of Mental Disorders. 5th ed. American Psychiatric Association; 2013.
2.
Roth  T , Jaeger  S , Jin  R , Kalsekar  A , Stang  PE , Kessler  RC .  Sleep problems, comorbid mental disorders, and role functioning in the national comorbidity survey replication.   Biol Psychiatry. 2006;60(12):1364-1371. doi:10.1016/j.biopsych.2006.05.039PubMedGoogle ScholarCrossref
3.
Morin  CM , Bélanger  L , LeBlanc  M ,  et al.  The natural history of insomnia: a population-based 3-year longitudinal study.   Arch Intern Med. 2009;169(5):447-453. doi:10.1001/archinternmed.2008.610PubMedGoogle ScholarCrossref
4.
Baglioni  C , Battagliese  G , Feige  B ,  et al.  Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies.   J Affect Disord. 2011;135(1-3):10-19. doi:10.1016/j.jad.2011.01.011PubMedGoogle ScholarCrossref
5.
Vgontzas  AN , Fernandez-Mendoza  J , Liao  D , Bixler  EO .  Insomnia with objective short sleep duration: the most biologically severe phenotype of the disorder.   Sleep Med Rev. 2013;17(4):241-254. doi:10.1016/j.smrv.2012.09.005PubMedGoogle ScholarCrossref
6.
Laugsand  LE , Vatten  LJ , Platou  C , Janszky  I .  Insomnia and the risk of acute myocardial infarction: a population study.   Circulation. 2011;124(19):2073-2081. doi:10.1161/CIRCULATIONAHA.111.025858PubMedGoogle ScholarCrossref
7.
Parthasarathy  S , Vasquez  MM , Halonen  M ,  et al.  Persistent insomnia is associated with mortality risk.   Am J Med. 2015;128(3):268-75.e2. doi:10.1016/j.amjmed.2014.10.015PubMedGoogle ScholarCrossref
8.
Daley  M , Morin  CM , LeBlanc  M , Grégoire  JP , Savard  J .  The economic burden of insomnia: direct and indirect costs for individuals with insomnia syndrome, insomnia symptoms, and good sleepers.   Sleep. 2009;32(1):55-64.PubMedGoogle Scholar
9.
Buysse  DJ .  Insomnia.   JAMA. 2013;309(7):706-716. doi:10.1001/jama.2013.193PubMedGoogle ScholarCrossref
10.
Morin  CM , Benca  R .  Chronic insomnia.   Lancet. 2012;379(9821):1129-1141. doi:10.1016/S0140-6736(11)60750-2PubMedGoogle ScholarCrossref
11.
van Straten  A , Cuijpers  P .  Self-help therapy for insomnia: a meta-analysis.   Sleep Med Rev. 2009;13(1):61-71. doi:10.1016/j.smrv.2008.04.006PubMedGoogle ScholarCrossref
12.
Qaseem  A , Kansagara  D , Forciea  MA , Cooke  M , Denberg  TD ; Clinical Guidelines Committee of the American College of Physicians.  Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians.   Ann Intern Med. 2016;165(2):125-133. doi:10.7326/M15-2175PubMedGoogle ScholarCrossref
13.
Riemann  D , Baglioni  C , Bassetti  C ,  et al.  European guideline for the diagnosis and treatment of insomnia.   J Sleep Res. 2017;26(6):675-700. doi:10.1111/jsr.12594PubMedGoogle ScholarCrossref
14.
Sateia  MJ , Buysse  DJ , Krystal  AD , Neubauer  DN , Heald  JL .  Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline.   J Clin Sleep Med. 2017;13(2):307-349. doi:10.5664/jcsm.6470PubMedGoogle ScholarCrossref
15.
van Straten  A , van der Zweerde  T , Kleiboer  A , Cuijpers  P , Morin  CM , Lancee  J .  Cognitive and behavioral therapies in the treatment of insomnia: a meta-analysis.   Sleep Med Rev. 2018;38:3-16. doi:10.1016/j.smrv.2017.02.001PubMedGoogle ScholarCrossref
16.
Wilson  SJ , Nutt  DJ , Alford  C ,  et al.  British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders.   J Psychopharmacol. 2010;24(11):1577-1601. doi:10.1177/0269881110379307PubMedGoogle ScholarCrossref
17.
Morin  CM , Colecchi  C , Stone  J , Sood  R , Brink  D .  Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial.   JAMA. 1999;281(11):991-999. doi:10.1001/jama.281.11.991PubMedGoogle ScholarCrossref
18.
Jacobs  GD , Pace-Schott  EF , Stickgold  R , Otto  MW .  Cognitive behavior therapy and pharmacotherapy for insomnia: a randomized controlled trial and direct comparison.   Arch Intern Med. 2004;164(17):1888-1896. doi:10.1001/archinte.164.17.1888PubMedGoogle ScholarCrossref
19.
Wu  R , Bao  J , Zhang  C , Deng  J , Long  C .  Comparison of sleep condition and sleep-related psychological activity after cognitive-behavior and pharmacological therapy for chronic insomnia.   Psychother Psychosom. 2006;75(4):220-228. doi:10.1159/000092892PubMedGoogle ScholarCrossref
20.
Sivertsen  B , Omvik  S , Pallesen  S ,  et al.  Cognitive behavioral therapy vs zopiclone for treatment of chronic primary insomnia in older adults: a randomized controlled trial.   JAMA. 2006;295(24):2851-2858. doi:10.1001/jama.295.24.2851PubMedGoogle ScholarCrossref
21.
Morin  CM , Vallières  A , Guay  B ,  et al.  Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: a randomized controlled trial.   JAMA. 2009;301(19):2005-2015. doi:10.1001/jama.2009.682PubMedGoogle ScholarCrossref
22.
Morin  CM , Edinger  JD , Krystal  AD , Buysse  DJ , Beaulieu-Bonneau  S , Ivers  H .  Sequential psychological and pharmacological therapies for comorbid and primary insomnia: study protocol for a randomized controlled trial.   Trials. 2016;17(1):118. doi:10.1186/s13063-016-1242-3PubMedGoogle ScholarCrossref
23.
Bastien  CH , Vallières  A , Morin  CM .  Validation of the Insomnia Severity Index as an outcome measure for insomnia research.   Sleep Med. 2001;2(4):297-307. doi:10.1016/S1389-9457(00)00065-4PubMedGoogle ScholarCrossref
24.
Morin  CM , Belleville  G , Bélanger  L , Ivers  H .  The Insomnia Severity Index: psychometric indicators to detect insomnia cases and evaluate treatment response.   Sleep. 2011;34(5):601-608. doi:10.1093/sleep/34.5.601PubMedGoogle ScholarCrossref
25.
Spielman  AJ , Saskin  P , Thorpy  MJ .  Treatment of chronic insomnia by restriction of time in bed.   Sleep. 1987;10(1):45-56.PubMedGoogle Scholar
26.
Bootzin  RR , Epstein  D , Wood  JM . Stimulus Control Instructions. In: Hauri  P , ed.  Case Studies in Insomnia. Plenum Press; 1991:19-28. doi:10.1007/978-1-4757-9586-8_2
27.
Harvey  AG , Sharpley  AL , Ree  MJ , Stinson  K , Clark  DM .  An open trial of cognitive therapy for chronic insomnia.   Behav Res Ther. 2007;45(10):2491-2501. doi:10.1016/j.brat.2007.04.007PubMedGoogle ScholarCrossref
28.
Morin  CM , Espie  CA .  Insomnia: A Clinical Guide to Assessment and Treatment. Kluwer Academic/Plenum; 2003.
29.
Harvey  AG .  Insomnia, psychiatric disorders, and the transdiagnostic perspective.   Curr Dir Psychol Sci. 2008;17(5):299-303. doi:10.1111/j.1467-8721.2008.00594.xGoogle ScholarCrossref
30.
Cascade  EF , Kalali  AH , Reites  J .  Current status of hypnotic prescribing habits in the United States.   Psychiatry (Edgmont). 2007;4(9):24-25.PubMedGoogle Scholar
31.
Wilt  TJ , MacDonald  R , Brasure  M ,  et al.  Pharmacologic treatment of insomnia disorder: an evidence report for a clinical practice guideline by the american college of physicians.   Ann Intern Med. 2016;165(2):103-112. doi:10.7326/M15-1781PubMedGoogle ScholarCrossref
32.
Asnis  GM , Chakraburtty  A , DuBoff  EA ,  et al.  zolpidempidem for persistent insomnia in SSRI-treated depressed patients.   J Clin Psychiatry. 1999;60(10):668-676. doi:10.4088/JCP.v60n1005PubMedGoogle ScholarCrossref
33.
Walsh  JK .  Drugs used to treat insomnia in 2002: regulatory-based rather than evidence-based medicine.   Sleep. 2004;27(8):1441-1442. doi:10.1093/sleep/27.8.1441PubMedGoogle ScholarCrossref
34.
Krystal  AD .  A compendium of placebo-controlled trials of the risks/benefits of pharmacological treatments for insomnia: the empirical basis for U.S. clinical practice.   Sleep Med Rev. 2009;13(4):265-274. doi:10.1016/j.smrv.2008.08.001PubMedGoogle ScholarCrossref
35.
Nierenberg  AA , Adler  LA , Peselow  E , Zornberg  G , Rosenthal  M .  trazodoneodone for antidepressant-associated insomnia.   Am J Psychiatry. 1994;151(7):1069-1072. doi:10.1176/ajp.151.7.1069PubMedGoogle ScholarCrossref
36.
Walsh  JK , Erman  M , Erwin  C .  Subjective hypnotic efficacy of trazodone and zolpidem in DSM-III-R primary insomnia.   Hum Psychopharmacol. 1998;13:191-198. doi:10.1002/(SICI)1099-1077(199804)13:3<191::AID-HUP972>3.0.CO;2-XGoogle ScholarCrossref
37.
Nahum-Shani  I , Qian  M , Almirall  D ,  et al.  Experimental design and primary data analysis methods for comparing adaptive interventions.   Psychol Methods. 2012;17(4):457-477. doi:10.1037/a0029372PubMedGoogle ScholarCrossref
38.
Robins  JM , Rotnitzky  A , Zhao  L .  Analysis of semiparametric regression models for repeated outcomes in the presence of missing data.   J Am Stat Assoc. 1995;90(429):106-121. doi:10.1080/01621459.1995.10476493Google ScholarCrossref
39.
European Medicines Agency (EMA).  Guideline on Adjustment for Baseline Covariates in Clinical Trials (No. EMA/CHMP/295050/2013). European Medicines Agency; 2015.
40.
Dahmen  G , Rochon  J , König  IR , Ziegler  A .  Sample size calculations for controlled clinical trials using generalized estimating equations (GEE).   Methods Inf Med. 2004;43(5):451-456. doi:10.1055/s-0038-1633896PubMedGoogle ScholarCrossref
41.
Harvey  AG , Dong  L , Bélanger  L , Morin  CM .  Mediators and treatment matching in behavior therapy, cognitive therapy and cognitive behavior therapy for chronic insomnia.   J Consult Clin Psychol. 2017;85(10):975-987. doi:10.1037/ccp0000244PubMedGoogle ScholarCrossref
42.
Harvey  AG , Murray  G , Chandler  RA , Soehner  A .  Sleep disturbance as transdiagnostic: consideration of neurobiological mechanisms.   Clin Psychol Rev. 2011;31(2):225-235. doi:10.1016/j.cpr.2010.04.003PubMedGoogle ScholarCrossref
Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Close
Close

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close